Oppenheimer Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target upped by investment analysts at Oppenheimer from $95.00 to $105.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 39.23% from the stock’s current price.

Several other research analysts have also weighed in on the stock. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. The Goldman Sachs Group reissued a “neutral” rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Barclays began coverage on Tarsus Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $100.00 price objective for the company. Finally, Wall Street Zen raised Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $87.00.

Tarsus Pharmaceuticals Price Performance

TARS stock traded up $0.41 on Wednesday, reaching $75.42. 368,671 shares of the company’s stock were exchanged, compared to its average volume of 622,685. The stock has a fifty day moving average of $72.25 and a 200-day moving average of $68.35. The firm has a market cap of $3.20 billion, a PE ratio of -46.55, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a quick ratio of 4.25, a current ratio of 4.29 and a debt-to-equity ratio of 0.22. Tarsus Pharmaceuticals has a twelve month low of $38.51 and a twelve month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.73% and a negative net margin of 14.72%.The company had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $144.56 million. As a group, equities analysts predict that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Dianne C. Whitfield sold 7,397 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the sale, the insider directly owned 38,958 shares in the company, valued at $3,120,535.80. This represents a 15.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total value of $495,060.00. Following the sale, the chief executive officer owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This represents a 0.69% decrease in their position. The SEC filing for this sale provides additional information. 8.97% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Tarsus Pharmaceuticals by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock valued at $1,137,000 after buying an additional 1,217 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Tarsus Pharmaceuticals by 2.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock worth $3,659,000 after purchasing an additional 1,394 shares during the period. Jane Street Group LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 105.8% during the first quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock worth $537,000 after purchasing an additional 190,000 shares during the last quarter. Allianz Asset Management GmbH purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at $227,000. Finally, Envestnet Asset Management Inc. increased its stake in Tarsus Pharmaceuticals by 15.9% in the second quarter. Envestnet Asset Management Inc. now owns 10,356 shares of the company’s stock valued at $420,000 after purchasing an additional 1,418 shares during the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target to $90 and kept a “buy” rating, implying ~20% upside from recent levels — a clear analyst endorsement that supports upside momentum. Benzinga
• Positive Sentiment: HC Wainwright published a very bullish long‑term view, raising FY2030 EPS estimates to $6.36 per share (well above current consensus), signaling confidence in XDEMVY’s multi‑year earnings potential. MarketBeat
• Positive Sentiment: Tarsus gave 2026 sales guidance of $670M–$700M and management reiterated a >$2B peak sales target for XDEMVY, plus international launch timing (China 2026, Europe 2027) — fundamental drivers that justify higher multiple expectations if execution continues. Seeking Alpha: 2026 sales guidance
• Positive Sentiment: Analyst commentary and notes (Seeking Alpha) emphasize XDEMVY’s rapid adoption (FY2025 revenue +150% to $451M) and margin profile (≈93%), supporting expectations for strong future cash flows even though profitability is forecasted to arrive in 2027. Seeking Alpha: Q4 results highlight
• Neutral Sentiment: Q4 revenue beat — $151.67M reported vs. ~$144.56M expected — which confirms demand, but investors will watch margins and cadence of future sales. Press Release / Slide Deck
• Neutral Sentiment: Earnings call transcript and slide deck are available for deeper read — useful for investors assessing guidance assumptions and international rollout plans. Seeking Alpha: Call Transcript
• Negative Sentiment: Q4 EPS missed slightly: a ($0.20) loss vs. consensus ($0.19) — a small miss but it keeps profitability off the near‑term table and highlights continuing negative net margin and ROE. Zacks

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.